Sermorelin Compounding Pharmacy Quality Red Flags to Avoid

Sermorelin is not FDA-approved today

Geref (sermorelin acetate, EMD Serono) was the only approved sermorelin, under two applications: NDA 019863, a 0.05 mg per ampule product approved in 1990 for testing the pituitary's ability to secrete growth hormone, and NDA 020443, 0.5 mg and 1 mg vials approved in 1997 for idiopathic growth hormone deficiency in children with growth failure [1]. Those two are the only sermorelin applications in Drugs@FDA [1][6].

The maker discontinued Geref in 2008 and asked FDA to withdraw the applications, which FDA did effective June 18, 2009 [1]. In March 2013 FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness [1].

With Geref withdrawn, sermorelin products sold in the US today are compounded, not FDA-approved [3]. FDA does not review a compounded drug's safety, effectiveness or quality before it is marketed [2]. Geref's approved uses were pediatric growth hormone deficiency and a pituitary diagnostic test; it was never approved for adults, anti-aging, weight loss or athletic performance [1].

Red flag 1: nobody will tell you who compounded it

FDA describes compounding by state-licensed pharmacies, FDA-registered outsourcing facilities, physicians and federal facilities [2]. Outsourcing facilities are overseen primarily by FDA, inspected on a risk-based schedule, and subject to current good manufacturing practice requirements. State boards of pharmacy have primary day-to-day responsibility for state-licensed pharmacies that are not outsourcing facilities, though FDA conducts surveillance and for-cause inspections of them. Drugs compounded by a pharmacist in a state-licensed pharmacy or by a physician, under the statutory conditions that apply to that kind of compounding, are not subject to those manufacturing requirements [2].

FDA also notes that people who buy compounded drugs online may not know which compounder made the drug, whether that compounder meets appropriate quality standards, or whether it is appropriately licensed and regulated [2]. A seller that will not name the compounding entity or explain how it is licensed or registered has not answered the first question a buyer should ask.

Red flag 2: the listing says FDA has checked the product

A page describing sermorelin as FDA-approved is wrong on the facts [1]. The Geref approvals were the only ones that existed, they covered two pediatric and diagnostic uses, and they were withdrawn in 2009 [1]. A seller that implies FDA has verified the potency, sterility or purity of its vials is contradicting FDA's own description of compounded drugs, which are not reviewed for safety, effectiveness or quality before marketing [2].

Red flag 3: marketing for anti-aging, weight loss or performance

Geref's approved indications were idiopathic growth hormone deficiency in children and a diagnostic test of pituitary growth hormone reserve [1]. Adult anti-aging, weight-loss and athletic uses were never approved [1]. Sermorelin is a 29-amino-acid GHRH analogue that prompts the pituitary to release growth hormone; it is not growth hormone itself [7].

What FDA says can go wrong with poor compounding

FDA lists the practical failure modes directly: poor compounding practices can cause serious drug quality problems such as contamination, or a drug that contains too much or too little active ingredient, and those can lead to serious injury and death [2]. FDA also publishes warning letters, listed by company and subject, including letters from its drug center for unapproved new drugs and CGMP problems [8].

Where sermorelin sits on FDA's bulk-substance lists

Sermorelin is not on FDA's list of bulk substances that may present significant safety risks when compounded [4]. On FDA's nomination list for outsourcing facilities, sermorelin acetate sits in category 1, under evaluation, marked as a substance that is a component of FDA-approved drugs [5]. It does not appear in any category on the list for state-licensed pharmacies and physicians [9], and it is not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [10].

For contrast, FDA lists two related growth-hormone-releasing peptides, GHRP-2 (injectable and nasal routes) and GHRP-6, among bulk substances that may present significant safety risks [4].

What the clinical studies measured

The pivotal pediatric study enrolled 110 previously untreated prepubertal children with growth hormone deficiency; 86 were evaluable. They received 30 micrograms per kg of GHRH(1-29) subcutaneously once daily at bedtime for up to a year. Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months, and 74% were good responders at 6 months. The study reported no adverse changes in general biochemistry or hormone tests, no change in fasting glucose, and no excessive rise in IGF-I [11].

A separate short physiology study gave 10 healthy older men (mean age 68) 0.5 mg or 1 mg of GHRH(1-29) subcutaneously twice daily for 14 days each, and compared them with 9 younger men. At the high dose, 24-hour growth hormone and IGF-I rose to levels not significantly different from the young men. It measured hormone levels, not clinical outcomes [12]. These are study regimens, not recommended doses, and neither study tested the quality of any pharmacy's product.

Checks that follow from the record

• Identify the compounder and how it is licensed or registered: state-licensed pharmacy, FDA-registered outsourcing facility, physician or federal facility [2].
• Search that name in FDA's warning letters [8].
• Treat 'FDA-approved sermorelin' as a factual error [1].
• Treat anti-aging, weight-loss and performance marketing as outside every use sermorelin was ever approved for [1].
• Check FDA's bulk-substance lists rather than a seller's summary of them [4][5].

HealthRX.com offers sermorelin by prescription.